• S2:E3 – SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action

  • Mar 30 2021
  • Length: 24 mins
  • Podcast

S2:E3 – SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action

Listen for free

View show details

  • Summary

  • Visit http://morningcommutepodcast.com/SGLT2inhibitors6 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, Dr. James Januzzi and Dr. Silvio Inzucchi discuss the surge in collaboration between primary care physicians, endocrinologists, and cardiologists and the groundswell of cardiometabolic clinics. They attribute this to cardiologists moving beyond the so-called glucocentric view and focusing on how diabetes therapies might help reduce cardiovascular risk as well. Drs. Januzzi and Inzucchi will also discuss the recent guidelines that now incorporate sodium-glucose cotransporter 2 (SGLT-2) inhibitors into clinical pathways.
    Show more Show less
activate_primeday_promo_in_buybox_DT
Show more Show less

What listeners say about S2:E3 – SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available